Please use this identifier to cite or link to this item:
Title: Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.
Authors: Brenner, Bluma G
Thomas, Réjean
Blanco, José Luis
Ibanescu, Ruxandra-Ilinca
Oliveira, Maureen
Mesplède, Thibault
Golubkov, Olga
Roger, Michel
Garcia, Federico
Martinez, Esteban
Wainberg, Mark A
metadata.dc.subject.mesh: Adult
Drug Resistance, Viral
Genotyping Techniques
HIV Infections
HIV Integrase
HIV Integrase Inhibitors
Heterocyclic Compounds, 3-Ring
Microbial Sensitivity Tests
Middle Aged
Mutation, Missense
Treatment Failure
Issue Date: 29-Mar-2016
Abstract: Dolutegravir shows a high barrier to resistance with no previously reported cases of acquired integrase mutations during first-line therapy. In this study, rapid development of the G118R mutation arose following a switch from first-line elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine to dolutegravir monotherapy. The G118R mutation also arose in a treatment-experienced patient switched to dolutegravir monotherapy. The genetic basis for G118R selection and potential phenotypic outcome was ascertained. Genotypic analysis was performed on patients with virological failure ( We report on two patients who developed viral failure while on dolutegravir monotherapy. Both patients had been on a current or previous regimen containing integrase inhibitors. Virological failure ( Although resistance to dolutegravir is typically rare, genetic polymorphisms and monotherapy can facilitate the acquisition of G118R.
metadata.dc.identifier.doi: 10.1093/jac/dkw071
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.